Table 5 Demographic and clinical characteristics of study cohorts after matching
From: Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States
| Â | AATD-COPD COHORT (CASES) | NON-AATD-COPD COHORT (CONTROLS) | ||
|---|---|---|---|---|
N = 953 | N = 7,928 | |||
No. of patients | (Column %) / [median] | No. of patients | (Column %) / [median] | |
Age, mean (SD) | 56.24 (10.74) | [56] | 55.17 (9.62) | [56] |
Age categories, n (%) | ||||
 30 - 39 | 57 | (6) | 445 | (6) |
 40 - 49 | 191 | (20) | 1,697 | (20) |
 50 - 59 | 355 | (37) | 3,194 | (37) |
 60 - 64 | 174 | (18) | 1,537 | (18) |
 >=65 | 176 | (18) | 1,055 | (18) |
Gender, n (%) | ||||
 Male | 456 | (48) | 3,812 | (48) |
 Female | 497 | (52) | 4,116 | (52) |
Race/Ethnicity a , n (%) | ||||
 White | 877 | (92) | 7,526 | (95) |
 African American | 39 | (4) | 201 | (3) |
 Hispanic | 33 | (3) | 195 | (2) |
Census region, n (%) | ||||
 Northeast | 104 | (11) | 104 | (11) |
 Midwest | 287 | (30) | 287 | (30) |
 South | 414 | (43) | 414 | (43) |
 West | 148 | (16) | 148 | (16) |
Charlson Comorbidity Score a , n (%) | ||||
 1 | 596 | (63) | 5,416 | (68) |
 2 | 161 | (17) | 1,282 | (16) |
 3 | 90 | (9) | 592 | (7) |
 4 | 40 | (4) | 207 | (3) |
  ≥5 | 66 | (7) | 431 | (5) |